Advertisement
Advertisement
XENE
Xenon Pharmaceuticals Inc
54.39
USDSponsored
-1.61
-2.87%
May 15, 15:59 UTC -4
Closed
After-Market
53.63
-0.77
-1.41%
XENE Earnings Reports
Positive Surprise Ratio
XENE beat 24 of 42 last estimates.
57%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.39M
/-$1.15
Implied change from Q1 26 (Revenue/ EPS)
--
/-1.71%
Implied change from Q2 25 (Revenue/ EPS)
--
/+7.48%
Xenon Pharmaceuticals Inc earnings per share and revenue
On May 07, 2026, XENE reported earnings of -1.17 USD per share (EPS) for Q1 26, beating the estimate of -1.20 USD, resulting in a 3.14% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.79% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -1.15 USD, with revenue projected to reach 1.39 million USD, implying an decrease of -1.71% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Satellos Bioscience Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.61
Actual
-$0.53
Surprise
+13.58%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.04
Surprise
+12.85%
Citius Oncology, Inc. Common Stock
Report Date
May 15, 2026 For Q2 26
Estimate
-$0.01
Actual
-$1.43
Surprise
-13919.61%
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
Sensei Biotherapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.63
Actual
-$28.79
Surprise
-4452.50%
Neuphoria Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.98
Actual
-$0.09
Surprise
+90.90%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
Cocrystal Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
GT Biopharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.08
Actual
-$0.11
Surprise
-34.80%
FAQ
What were Xenon Pharmaceuticals Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Xenon Pharmaceuticals Inc reported EPS of -$1.17, beating estimates by 3.14%, and revenue of $0.00, 0% as expectations.
How did the market react to Xenon Pharmaceuticals Inc's Q1 2026 earnings?
The stock price moved up 0.79%, changed from $56.00 before the earnings release to $56.44 the day after.
When is Xenon Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Xenon Pharmaceuticals Inc's next earnings report?
Based on 13
analysts, Xenon Pharmaceuticals Inc is expected to report EPS of -$1.15 and revenue of $1.39M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement